CliffBio
small molecule

TOBRAMYCIN SULFATE

TOBRAMYCIN SULFATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameTOBRAMYCIN SULFATE
Active ingredientTOBRAMYCIN SULFATE
StrengthEQ 1.2GM BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2004
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.